- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.07. | Life sciences VC Omega Funds closes $647m funding round | ||
| 21.07. | Sarepta refuses to pull gene therapy despite FDA order | ||
| 21.07. | Five considerations when scaling up mAbs in partnership with a CDMO | ||
| 21.07. | CDMO insights podcast series: Our Experience is Your Strength | Episode #2 Gene Therapy Fill-Finish | ||
| 21.07. | Sanofi concludes Blueprint Medicines acquisition | ||
| 21.07. | Fangzhou and Novo Nordisk link on chronic disease management | ||
| 18.07. | Astellas and KISED link to support Korean pharma startups | ||
| 18.07. | ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing | ||
| 18.07. | FDA approves GSK's prefilled syringe presentation of Shingrix | ||
| 18.07. | Can rare disease research in the US thrive under the new administration? | ||
| 17.07. | Ten years of Rare Pediatric Disease Designation: impact on drug approvals | ||
| 17.07. | Sarepta Therapeutics to cut 500 jobs amid restructuring | ||
| 17.07. | Thermo Fisher acquires Sanofi's steriles manufacturing site in US | ||
| 16.07. | PEPFAR funding protection offers "hope" for people living with HIV | ||
| 16.07. | UK government targets manufacturing as it eyes £41bn life science sector growth | ||
| 16.07. | GSK's Blenrep US comeback hindered by eye safety concerns | ||
| 16.07. | Why global 3PL providers are essential to easing supply chain challenges | ||
| 16.07. | Navamedic completes dne pharma acquisition | ||
| 16.07. | Acumen and JCR partner on brain delivery therapy for Alzheimer's | ||
| 15.07. | Sino Biopharma spends $951m to acquire China-based LaNova Medicines | ||
| 15.07. | Otsuka to acquire Cantargia's CAN10 for autoimmune diseases | ||
| 15.07. | Vertex and NHS England agree reimbursement for Alyftrek | ||
| 15.07. | LEO Pharma secures rights to Boehringer's Spevigo for $105m | ||
| 15.07. | Health Canada extends Evkeeza approval for children with HoFH | ||
| 14.07. | WHO endorses Gilead's Yeztugo for HIV prevention |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .